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Manganese and extracellular superoxide dismutases (SOD2 and SOD3) are part of the enzymatic defence against reactive oxygen
species,whichareinvolvedinthepathogenesisofasbestosis.Thisstudyinvestigateswhether SOD2Ala −9ValandSOD3Arg213Gly
genetic polymorphisms represent risk factors for asbestosis in workers exposed to asbestos. The study included 262 cases with
asbestosis and 265 controls with no asbestos-related disease. Cumulative asbestos exposure was calculated for each subject. A
real-time PCR assay was introduced for genotyping. Logistic regression analysis was used to assess asbestosis risk. Asbestosis was
associated with the homozygous SOD2 −9Ala/Ala genotype (OR = 1.50, 95% CI 1.01–2.24), whereas the association for the SOD3
Arg/Gly genotype was not signiﬁcant (OR = 1.63, 95% CI 0.62–4.27). The ﬁnding that the SOD2 −9Ala/Ala genotype increases
the risk for asbestosis indicates that, in addition to asbestos exposure, genetic factors may also have a signiﬁcant inﬂuence on the
development of asbestosis.
Copyright © 2009 Alenka Franko et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Exposure to asbestos ﬁbres has been shown to cause
asbestosis, pleural diseases such as pleural plaques, lung
cancer, malignant mesothelioma and some other types of
cancers [1–3]. One of the most frequent diseases caused by
inhalation of asbestos is asbestosis, an interstitial pulmonary
process that slowly develops into diﬀuse pulmonary ﬁbrosis
[4]. Although the causal relationship between asbestos
exposure and asbestosis has been well proved, little is still
known about the genetic factors that may inﬂuence the
development of this disease [2, 5]. At present it is suggested
that both environmental and genetic factors may play an
important role in the development of asbestosis [2, 6, 7].
The gene-environmental interaction studies published so far
have mostly focused on the genes coding for xenobiotic
metabolizing enzymes [2, 5–9].
Numerous studies have suggested the central role of
reactive oxygen and nitrogen species (ROS and RNS) in
ﬁbre-induced toxicity and development of asbestosis [1,
10, 11]. The most important reactive metabolites in the
pathogenesis of asbestos-related lung diseases are superoxide
anion (O2
•−), hydrogen peroxide (H2O2), hydroxyl radical
(OH
•) and nitric oxide (NO) [10, 12, 13].
Human tissues contain speciﬁc enzyme systems to
detoxify ROS and RNS. Superoxide dismutases (SODs)
together with catalase and glutathione peroxidases constitute
a primary defence against oxidative stress [10, 14, 15].
SODs catalyze the conversion of superoxide anion (O2
•− )
to hydrogen peroxide (H2O2) and oxygen (O2)[ 14, 16].
Manganese SOD (MnSOD or SOD2) is a manganese (Mn)-
containingenzymelocalizedinmitochondria,whereasextra-
cellular SOD (ECSOD or SOD3), which contains copper
(Cu) and zinc (Zn), is predominantly found in extracellular
space [14, 15].
In humans, SOD2 is encoded by the SOD2 gene localized
to chromosome 6 (region 6q25), and SOD3 by the SOD3
gene, which has been localized to chromosome 4 (region 4p-
q21) [15, 17, 18]. The genes coding for SOD2 and SOD3 are
polymorphic. The most common functional polymorphism
of the SOD2 gene is cytosine (C) to thymine (T) substitution
(201C>T, rs4880), which results in alanine (Ala) to valine
(Val) amino acid change at position −9 of the mitochondrial
targeting sequence (SOD2 Ala −9Val) [19, 20]. It has2 Journal of Biomedicine and Biotechnology
been suggested that this polymorphism alters the secondary
structure of the protein, and hence may aﬀect the eﬃciency
of transport of the SOD2 into the mitochondria, where
it would be biologically available [19, 20]. Sutton et al.
demonstrated that Ala-containing SOD2 is actively targeted
into the mitochondrial matrix, whereas the Val-containing
variant is partially arrested within the inner mitochondrial
membrane [21]. The Ala-variant also resulted in 4-fold
higher levels of the mature exogenous protein and SOD2
activity than the Val-variant [21]. The frequency of each
allele is around 50% in Caucasian populations [22], whereas
the Val allele is more frequent in Japan (87.9%) [19]. Among
asbestos-related diseases, the SOD2 −9Val/Val genotype was
associated with increased lung cancer risk in individuals
with a low asbestos exposure score [23], whereas another
study found an increased risk of mesothelioma in subjects
with the SOD2 −9Ala/Ala genotype [24]. In contrast, a
study by Hirvonen et al. suggested no major modifying
role for SOD2 polymorphism in asbestos-related pulmonary
disorders [9].
SOD3 binds lung matrix components and inhibits their
fragmentation in response to oxidative stress [25, 26]. In
the SOD3 gene, a cytosine (C) to guanine (G) substitution
(896C>G, rs1799895) causing an amino acid change from
arginine (Arg) to glycine (Gly) at position 213 has been
reported (Arg213Gly) [15, 27, 28]. Although this polymor-
phism is rare, occurring in 2 to 6% of various populations
[15, 27, 28], it causes an 8- to 15-fold increase in the con-
centration of plasma SOD3 levels due to impaired binding
to the extracellular matrix [27, 28]. To our knowledge, the
inﬂuence of SOD3 Arg213Gly polymorphism on the risk
of developing asbestosis in workers exposed to asbestos
has not been studied so far. Most of the data come from
studies on SOD3 transgenic [29, 30] and knockout mice
[31, 32] that clearly demonstrate the importance of SOD3
in lung protection. Enhanced lung damage, inﬂammation,
and ﬁbrosis were observed in SOD3 knockout mice com-
pared to wild-type mice in asbestos-induced lung injuries
[25, 32, 33].
To studytheinﬂuenceofgeneticpolymorphisms ofsome
of the most important metabolic enzymes on the risk for
asbestosis and possible interaction with asbestos exposure,
the authors designed a series of molecular epidemiological
studies [6, 7]. The basic aim of this study was to investigate
the inﬂuence of the SOD2 Ala −9Val and SOD3 Arg213Gly
genetic polymorphisms on the risk for developing asbestosis
in workers occupationally exposed to asbestos.
2. Methods
In a nested case-control study, all 356 subjects diagnosed
with asbestosis were ﬁrst selected from the cohort of 2080
workers that were presented at the State Board for the
Recognition of Occupational Asbestos Diseases from 1
January 1998 to 31 December 2003. For each case, one
control with no asbestos-related disease was recruited from
the same cohort using gender and date of birth as matching
factors.
From the selected subjects, 2 cases and 9 controls
developed cancer in the period between the recognition of
the occupational disease and the beginning of the study,
40 cases and 29 controls died during the same period, and
52 cases and 53 controls refused to participate, so the ﬁnal
number of cases was 262 (73.6%) and that of controls 265
(74.4%).
Information about smoking, including duration of
smoking and the number of pack-years of smoking, was
obtained for all subjects during an interview using a
standardized questionnaire [3, 34].
All subjects that participated in the study worked at
the Salonit Anhovo asbestos cement manufacturing plant
in Anhovo, Slovenia and were occupationally exposed to
asbestos [3]. For each case and control included in this study,
the data on cumulative asbestos exposure were available
from the previous study [3]. The methodology of cumulative
asbestos exposure calculation has already been described in
detail in previous papers [3, 6].
The diagnosis of asbestosis or “no asbestos-related
disease” was conﬁrmed by two groups of experts from the
State Board for the Recognition of Occupational Asbestos
DiseasesthatoperateattheClinicalInstituteofOccupational
Medicine;eachgroupconsistedofanoccupationalphysician,
a pulmonologist, and a radiologist. The diagnostic criteria
were based on the Helsinki Criteria for Diagnosis and
Attribution of Asbestos Diseases [35] and on the American
Thoracic Society recommendations [36].
For genetic analysis, capillary blood samples from the
ﬁ n g e r t i p so fa l ls u b j e c t sw e r ec o l l e c t e do nF T AM i n iC a r d s
(Whatman Bioscience) and genomic DNA was isolated as
previously described [6].
To determine SOD2 Ala −9Val and SOD3 Arg213Gly
polymorphisms, TaqMan SNP genotyping assays were used
(C 8709053 10 and C 2307506 10, resp., AB assay, Applied
Biosystems, Foster City, Calif. USA). Real-time PCR was
performed under universal conditions on ABI 7500 (Applied
Biosystems, Foster City, Calif. USA). TaqMan SNP genotyp-
ing assays were validated on 100 samples genotyped by the
PCR-RFLP method. To determine SOD2 Ala −9Val poly-
morphism, the region encompassing the polymorphic site
was ampliﬁed and PCR products were digested withNgoM
IV (New England Biolabs), as previously described [37]. To
determineSOD3Arg213Glypolymorphism,thecorrespond-
ing PCR products were digested with MwoI (New England
Biolabs), as previously described [38].
Amongstatisticalmethods,standarddescriptivestatistics
were ﬁrst performed. Next, t-tests for diﬀerences of means
of variables between the cases and controls were calculated,
and χ2 tests were used to determine whether the observed
diﬀerences in proportions between the study groups were
statistically signiﬁcant. To assess the causal relationship
betweenasbestosis,genotypes,cumulativeasbestosexposure,
and standard confounders (age, sex), univariate logistic
regression was ﬁrst used, followed by multivariate logistic
regression modelling. A possible synergistic eﬀect between
genotypesandcumulativeasbestosexposurewasinvestigated
by using dummy variables. P-values less than 0.05 were
considered statistically signiﬁcant.Journal of Biomedicine and Biotechnology 3
Table 1: Smoking and cumulative asbestos exposure in cases and controls.
Cases (n = 262) Controls (n = 265) Test P-value
Smoking (ever/never smokers,n) 117/145 120/145 χ2 = 0.01 .919
Mean SD Range Mean SD Range
Years of smoking 25.92 13.37 0.01–60.00 22.90 12.90 1.00–61.00 t = 1.77 .078
Pack-years of smoking 21.92 15.95 0.15–66.25 20.99 16.37 0.05–90.00 t = 0.44 .659
Cumulative asbestos exposure (ﬁbres/cm3-years) 37.67 86.43 0.01–869.72 11.23 23.47 0.01–149.21 t = 4.78 .000
Table 2: Frequencies of SOD2 and SOD3 genotypes in cases and controls.
Cases (n = 258) Controls (n = 261)
SOD2 genotype n % n % χ2 P-value
Ala/Ala 75 29.0 56 21.4
Ala/Val 116 45.0 139 53.3 4.79∗ .029
Val/Val 67 26.0 66 25.3 1.25† .263
Ala/Val + Val/Val 183 71.0 205 78.6 3.99‡ .046
Cases (n = 258) Controls (n = 263)
SOD3 genotype n % n % χ2 P-value
Arg/Arg 247 95.7 256 97.3
Arg/Gly 11 4.3 7 2.7 1.00§ .317
Gly/Gly 0 0 0 0
∗χ2 calculated for Ala/Ala versus Ala/Val
†χ2 calculated for Ala/Ala versus Val/Val
‡χ2 calculated for Ala/Ala versus Ala/Val + Val/Val
§χ2 calculated for Arg/Arg versus Arg/Gly.
The study was approved by the Slovenian Ethics Com-
mittee for Research in Medicine and was carried out in line
with the Helsinki Declaration.
3. Results
There was no statistical diﬀerence in gender between the
cases and controls. Among the 262 cases there were 186 men
and 76 women, and among the 265 controls 183 men and
82 women (χ2 = 0.24, P = .628). On average, cases were
61 and controls 57 years old, showing a statistical diﬀerence
betweenthem(t = 5.18,P = .000).Nodiﬀerenceinsmoking
was observed between the cases and controls (Table 1).
As expected, the mean cumulative asbestos exposure was
higheramongthecasesthanthecontrols(t = 4.78,P = .000)
(Table 1).
All of the subjects were genotyped for SOD2 Ala −9Val
and SOD3 Arg213Gly polymorphisms, although the ampliﬁ-
cation of the SOD2 gene failed in 4 cases and 4 controls, and
that of the SOD3 gene in 4 cases and 2 controls.
Three diﬀerent SOD2 genotypes (Ala/Ala, Ala/Val, and
Val/Val) and two SOD3 genotypes (Arg/Arg and Arg/Gly)
were detected. The SOD2 −9Ala/Ala genotype was observed
in 29.0% of cases and 21.4% of controls, Ala/Val in 45.0%
of cases and 53.3% of controls, and Val/Val in 26.0% of
cases and 25.3% of controls. The SOD3 Arg/Arg genotype
was found in 95.7% of cases and 97.3% of controls, and the
Arg/Gly genotype was observed in 4.3% of cases and 2.7%
of controls. Combining polymorphic SOD2 genotypes, the
frequency of the −9Ala/Ala genotype versus the frequency
of the Ala/Val and Val/Val genotypes was signiﬁcantly higher
in the cases than in the controls (χ2 = 3.99, P = .046)
(Table 2). In contrast, no signiﬁcant diﬀerence was found in
the frequency of the SOD3 Arg/Arg genotype compared to
the frequency of the Arg/Gly genotype (χ2 = 1.00, P = .317)
(Table 2).
In subsequent logistic regression analysis, no association
was observed between asbestosis and ever/never smoking
(OR = 0.98, 95% CI 0.69–1.39). Knowing that cumulative
asbestos exposure was skewed to the right, logarithmically
transformed cumulative asbestos exposure was calculated,
giving an OR of asbestosis of 3.21 (95% CI 2.43–4.23).
Analyzing the association between asbestosis and SOD2
genotypes, the OR of asbestosis was 1.61 (95% CI 1.05–2.46)
for the −9Ala/Ala genotype versus the Ala/Val genotype,
1.32 (95% CI 0.81–2.14) for the Ala/Ala genotype versus
the Val/Val genotype, and 1.50 (95% CI 1.01–2.24) for
the Ala/Ala genotype versus combined Ala/Val and Val/Val
genotypes. The OR of asbestosis calculated for the SOD3
Arg/Gly genotype compared to the Arg/Arg genotype was
1.63 (95% CI 0.62–4.27).
Using multivariate logistic regression modelling, the
risk of asbestosis for the SOD2 −9Ala/Ala genotype versus
combined Ala/Val and Val/Val genotypes did not change
considerably after adjustment by gender, age, smoking, and
cumulative asbestos exposure (Table 3). The results showed
that gender, age, and smoking did not substantially inﬂuence4 Journal of Biomedicine and Biotechnology
Table 3: Risk of asbestosis for the SOD2 −9Ala/Ala versus combined Ala/Val and Val/Val genotypes and SOD3 Arg/Gly genotype compared
to Arg/Arg genotype after adjustment by gender, age, smoking, and cumulative asbestos exposure.
SOD2 −9Ala/Ala SOD3 Arg/Gly
OR 95% CI OR 95% CI
Unadjusted 1.50 1.01–2.24 1.63 0.62–4.27
Adjusted by
Gender 1.49 1.00–2.23 1.61 0.61–4.22
Age 1.46 0.97–2.19 1.49 0.56–3.96
Smoking (ever/never) 1.49 1.00–2.23 1.65 0.63–4.32
Cumulative exposure 1.48 0.96–2.28 2.07 0.72–5.94
the risk of asbestosis for the SOD3 Arg/Gly compared to
Arg/Arg genotype either, but the involvement of cumulative
asbestos exposure changed the OR from 1.63 (95% CI 0.62–
4.27) to 2.07 (95% CI 0.72–5.94), indicating a possible con-
founding eﬀect of cumulative asbestos exposure (Table 3).
To test the possible interaction between asbestos exposure
and the SOD3 genotype, a dummy variable was created by
multiplying the SOD3 Arg/Gly genotype and cumulative
asbestos exposure. No synergistic eﬀect was found (OR =
0.61, P = .456). When the SOD2 and SOD3 genotypes were
simultaneously introduced into logistic regression analysis,
the OR of asbestosis was 1.51 (95% CI 1.01–2.25) for the
SOD2 −9Ala/Ala genotype and 1.61 (95% CI 0.61–4.24) for
the SOD3 Arg/Gly genotype, showing independent activity
of the two.
4. Discussion
Increasing evidence suggests that both asbestos exposure and
genetic factors play an important role in the development
of asbestosis [2, 6–8], which is known to be among the
most frequent asbestos-related diseases. The key ﬁnding of
this study is that the SOD2 −9Ala/Ala genotype increases
risk of asbestosis. Although the function of SOD2 Ala
−9Val polymorphism requires further investigation and
elucidation,ithasbeensuggestedthathumanSOD2withAla
inthemitochondrialtargetingsequenceallowsmoreeﬃcient
import into the mitochondrial matrix and is therefore
presumed to result in higher levels of the mature SOD2
and enzyme activity than the Val-variant [19, 21]. In line
with these observations, it could be predicted that having
the SOD2 −9Ala/Ala genotype is beneﬁcial [39]. However,
several epidemiological studies have indicated an increased
risk of developing diseases in individuals carrying this
genotype[22,24,40,41].Thisdiscoveryisinagreementwith
the results of our study. In addition, it has been suggested
that SOD2 may play a dual role in relation to ROS [22].
On the one hand, SOD2 is considered to be a detoxifying
enzyme that removes superoxide anion [14, 16]. On the
other hand, it has been suggested that H2O2 generated by
SOD2 is toxic because it can be converted to the more toxic
OH
• radical if not removed quickly and eﬃciently enough
by glutathione peroxidase and catalase [21, 42]. An elevated
level of SOD2 activity could therefore result in increased
production of H2O2 and OH
• radicals, which can cause cell
injury and consequently a higher risk of developing diseases
[42]. In line with these reports and the assumption that
individuals with the SOD2 −9Ala/Ala genotype may have
higher SOD2 enzyme activity and therefore likely elevated
levels of H2O2 and OH
• radicals, which are known to
be involved in the pathogenesis of asbestosis, our ﬁnding
of an increased risk of asbestosis in subjects with the
SOD2 −9Ala/Ala genotype may be considered biologically
plausible.
In contrast to the observations of the present study,
Hirvonen et al. suggested no major modifying role for SOD2
polymorphism in asbestos-related pulmonary disorders in
a study based on 20 subjects with mesothelioma and 41
subjects with asbestosis or/and pleural plaques [9]. However,
Landi et al. found an increased risk of mesothelioma in
subjects with the SOD2 −9Ala/Ala genotype, which very
likely agrees with the ﬁndings of this study [24].
A slightly elevated risk of asbestosis was also observed
for the SOD3 Arg/Gly genotype, but the result was not
signiﬁcant. Despite the higher frequency of the SOD3
Arg/Gly genotype in subjects with asbestosis compared to
the controls, no signiﬁcant diﬀerence was observed due to
the lack of power. However, the results of several studies
demonstrated that SOD3 knockout mice show enhanced
lung damage, inﬂammation, and ﬁbrosis compared to wild-
type mice in asbestos-induced lung injuries [25, 32, 33, 43].
In line with these reports, SOD3 polymorphism might play
a role in developing asbestosis and should therefore be
further investigated in association with this disease. The
risk of asbestosis for the SOD3 Arg/Gly genotype increased
slightly after involvement of cumulative asbestos exposure.
No synergistic eﬀect was found, but cumulative asbestos
exposure acted as a confounder.
The ﬁndings of the current study were not biased
by genetic heterogeneity because all of the subjects were
recruited in a small geographic area with an ethnically
homogenous population. There were also no diﬀerences in
the cumulative exposure or diagnosis of cancer between the
participants and subjects that did not want to take part
in the study, died or developed a malignant disease in the
period between the recognition of occupational disease and
beginning of this study.
Overall, this study found evidence of an association
between asbestosis and SOD2 Ala −9Val genetic poly-
morphism. The results of our previous studies showedJournal of Biomedicine and Biotechnology 5
a decreased risk of asbestosis in individuals with the glu-
tathione S-transferase T1-null genotype [6] and an increased
risk in subjects carrying the glutathione S-transferase P1
genotype coding for an enzyme with high conjugation
capacity [7]. All of these results suggest that genetic factors
may have a signiﬁcant inﬂuence on the development of
asbestosis.Theseﬁndingsshouldalsobeseriouslyconsidered
in future research in association with other asbestos-related
diseases.Furthermore,toourknowledgethisistheﬁrststudy
investigating the role of SOD3 genetic variants in relation
to asbestosis in workers occupationally exposed to asbestos,
which is a topic that demands further investigation and
elucidation.
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